Patient Reported Outcomes Using Medical Cannabis for Managing Pain in Charcot-Marie-Tooth Disease
American Journal of Hospice and Palliative Medicine® · 2023
DOI: 10.1177/10499091231158388 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hospice and Palliative Medicine®, 2023. Verfasst von Priscilla C Canals und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, USA. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease, Medical Marijuana, Chronic Pain, Cannabis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Objective
Chronic pain is a major problem for patients with Charcot-Marie-Tooth (CMT) disease. This exploratory study examined patient reported efficacy of medical cannabis for pain management in this population.
Methods
Participants (N = 56; 71.4% female; Age = 48.9, SD = 14.6; 48.5% CMT1) were recruited though the Hereditary Neuropathy Foundation. The online survey contained 52 multiple choice questions about demographics, medical cannabis use, symptomology, efficacy, and adverse effects.
Results
Nearly all (90.9%) of respondents reported experiencing pain, including all (100%) females and 72.7% of males (chi-square P < .05) with 91.7% of respondents indicating cannabis provided at least 50% pain relief. The most frequent response was an 80% reduction in pain. Moreover, 80.0% of respondents reported using less opiates, 69% noted using less sleep medication, and 50.0% reported using less anxiety/antidepressant medications. Negative side effects were noted by 23.5% of respondents. However, almost all (91.7%) of that subgroup did not have plans to stop consuming cannabis. One-third (33.9%) possessed a medical cannabis certificate. Patient perceptions of their physicians’ attitudes regarding patient medical cannabis use greatly impacted whether respondents informed their providers of their usage.
Conclusion
The vast majority of patients with CMT reported that cannabis was effective to manage pain symptoms. These data support the need for prospective, randomized, controlled trials using standardized dosing protocols to further delineate and optimize the potential use of cannabis to treat pain related to CMT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, USA.
- Providence St Luke's Rehabilitation Medical Center, Hereditary Neuropathy Foundation Center of Excellence, Spokane, WA, USA.
- Real Isolates LLC, Beverly, MA, USA.
- CeresMed, South Burlington, VT, USA.
- Hereditary Neuropathy Foundation, New York, NY, USA.
- Center for Pharmacy Innovation and Outcomes, Precision Health Center, Forty Fort, PA, USA.
ORCID-Profile: Gregory T Carter
Zitieren
APA
Canals, P. C., Aguilar, A. G., Carter, G. T., Shields, C. M., Westerkamp, A., D'Elia, M., Aldrich, J., Moore, R. N., Moore, A. T., & Piper, B. J. (2023). Patient Reported Outcomes Using Medical Cannabis for Managing Pain in Charcot-Marie-Tooth Disease. American Journal of Hospice and Palliative Medicine®. https://doi.org/10.1177/10499091231158388
Vancouver
Canals PC, Aguilar AG, Carter GT, Shields CM, Westerkamp A, D'Elia M, et al. Patient Reported Outcomes Using Medical Cannabis for Managing Pain in Charcot-Marie-Tooth Disease. American Journal of Hospice and Palliative Medicine®. 2023. doi:10.1177/10499091231158388
BibTeX
@article{Canals2023,
author = {Canals, Priscilla C and Aguilar, Alexia G and Carter, Gregory T and Shields, C Miyabe and Westerkamp, Andrew and D'Elia, Meg and Aldrich, Joy and Moore, Robert N and Moore, Allison T and Piper, Brian J},
title = {Patient Reported Outcomes Using Medical Cannabis for Managing Pain in Charcot-Marie-Tooth Disease},
journal = {American Journal of Hospice and Palliative Medicine®},
year = {2023},
doi = {10.1177/10499091231158388}
}
EUVIMED